miR-96 promotes breast cancer metastasis by suppressing MTSS1

Abstract

Novel, non-invasive biomarkers with high sensitivity and specificity are critical for breast cancer treatment, and prognosis. MicroRNA (miR)-96 has been demonstrated to be highly expressed in several solid malignancies, including breast cancer. However, its expression and function in the metastasis and prognosis of breast cancer have not been fully explored, and its regulation mechanisms remain unclear. In the present study, the serum miR-96 expression in healthy controls, benign and malignant breast cancer types was compared by using reverse transcription-quantitative polymerase chain reaction. The effect of chemotherapy on miR-96 expression in breast cancer was also investigated. Result revealed that miR-96 expression was increased in malignant breast cancer types and reduced in patients following chemotherapy treatment. The effect of miR-96 manipulation on the migration of breast cancer cells was also investigated by using wound healing, and Transwell migration assays. These results revealed that the induced expression of miR96 led to enhanced wound closing and trans-membrane cell numbers. By using bioinformatics analysis, western blotting and immunohistochemical staining, the metastasis suppressor-1 (MTSS1) gene was identified to be the functional target of miR-96 in the promotion of cell migration. In conclusion, it was identified that miR-96 exhibited an increased level in serum samples of patients with malignant breast cancer in comparison with benign breast tumor types and health controls and may be substantially reduced by chemotherapy treatment, implying that it may be used as a prognostic marker in breast cancer. miR-96 overexpression may inhibit migration of breast cancer cells by downregulating MTSS1 expression.

Long non-coding RNA CASC2 inhibits breast cancer cell growth and metastasis through the regulation of the miR-96-5p/SYVN1 pathway

“…In BC, miR-96-5p is a positive regulator of the proliferation and metastasis processes, in which the miR-183-5p expression is increased (22)(23)(24)(25). In our previous study, SYVN1 was revealed to be a tumor suppressor in BC (26).…”

“…Furthermore, miR-96-5p expression is significantly elevated in BC tissues and cell lines compared with adjacent normal tissues and non-malignant breast epithelial cells, respectively (22,23). The overexpression of miR-96-5p promotes the proliferation and migration of BC cells, while the inhibition of miR-96-5p leads to a decrease in cell viability and an increase in cell death (24,25). miR-96-5p serves an oncogenic role in BC progression, but the regulatory mechanism requires further elucidation.…”

miR-96 Regulates Liver Tumor-Initiating Cells Expansion and Sorafenib Resistance

“…Accumulating evidence shows that miRNAs are involved in the regulation of human cancers and can be used as the diagnosis and therapeutic targets (20,21). For instance, miR-96 is upregulated in breast cancer and promotes breast cancer metastasis by suppressing MTSS1 (22). It was also reported that miR-96 works as a tumor repressor by inhibiting NPTX2 in renal cell carcinoma (23).…”

miR-96 regulates liver tumor-initiating cells expansion by targeting TP53INP1 and predicts Sorafenib resistance

“…Accumulating evidence shows that miRNAs are involved in the regulation of human cancers and can be used as the diagnosis and therapeutic targets [22,23]. For instance, miR-96 is upregulated in breast cancer and promotes breast cancer metastasis by suppressing MTSS1 [24]. It was also reported that miR-96 works as a tumor repressor by inhibiting NPTX2 in renal cell carcinoma [25].…”